[{"address1": "6550 South Millrock Drive", "address2": "Suite G50", "city": "Salt Lake City", "state": "UT", "zip": "84121", "country": "United States", "phone": "801 676 9695", "website": "https://clene.com", "industry": "Packaged Foods", "sector": "Consumer Defensive", "longBusinessSummary": "Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 82, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert  Etherington MBA", "age": 56, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1059310, "exercisedValue": 0, "unexercisedValue": 160201}, {"maxAge": 1, "name": "Mr. Morgan R. Brown CPA, M.B.A.", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 584885, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark G. Mortenson ESQ.", "age": 65, "title": "Chief Science Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 729918, "exercisedValue": 0, "unexercisedValue": 100803}, {"maxAge": 1, "name": "Mr. Jerry  Miraglia J.D.", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael T. Hotchkin", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Anne Mcneil", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Benjamin M. Greenberg M.D., M.H.S.", "title": "Head of Medical", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.66, "open": 6.66, "dayLow": 6.22, "dayHigh": 6.9, "regularMarketPreviousClose": 6.66, "regularMarketOpen": 6.66, "regularMarketDayLow": 6.22, "regularMarketDayHigh": 6.9, "beta": 0.48, "forwardPE": -1.4084821, "volume": 142921, "regularMarketVolume": 142921, "averageVolume": 118295, "averageVolume10days": 74630, "averageDailyVolume10Day": 74630, "bid": 6.17, "ask": 6.52, "bidSize": 100, "askSize": 100, "marketCap": 40826140, "fiftyTwoWeekLow": 3.82, "fiftyTwoWeekHigh": 14.0, "priceToSalesTrailing12Months": 92.36683, "fiftyDayAverage": 5.3758, "twoHundredDayAverage": 7.42895, "currency": "USD", "enterpriseValue": 54027648, "floatShares": 3366505, "sharesOutstanding": 6470070, "sharesShort": 158077, "sharesShortPriorMonth": 16772, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.024400001, "heldPercentInsiders": 0.33463, "heldPercentInstitutions": 0.15283, "shortRatio": 0.73, "shortPercentOfFloat": 0.0377, "bookValue": -0.078, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -30456000, "trailingEps": -3.07, "forwardEps": -4.48, "enterpriseToRevenue": 122.234, "enterpriseToEbitda": -1.571, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CLNN", "underlyingSymbol": "CLNN", "shortName": "Clene Inc.", "longName": "Clene Inc.", "firstTradeDateEpochUtc": 1539869400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c8c1753f-e5d6-313a-977a-f2458bf9394b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.31, "targetHighPrice": 100.0, "targetLowPrice": 20.0, "targetMeanPrice": 55.0, "targetMedianPrice": 31.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 21682000, "totalCashPerShare": 3.351, "ebitda": -34400000, "totalDebt": 32619000, "quickRatio": 0.816, "currentRatio": 0.994, "totalRevenue": 442000, "revenuePerShare": 0.069, "returnOnAssets": -0.41709, "returnOnEquity": -2.8965702, "freeCashflow": -14459625, "operatingCashflow": -27370000, "revenueGrowth": -0.662, "grossMargins": 0.80995005, "operatingMargins": -81.21978, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]